Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Risks of cancer and fungal infections are likely to grab a great deal of attention from the Gastrointestinal Drugs Advisory Committee when it reviews Centocor Ortho Biotech's Remicade (infliximab) for children July 21.
You may also be interested in...
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.